Literature DB >> 8760340

Molecular mechanisms of drug inhibition of DNA gyrase.

R J Lewis1, F T Tsai, D B Wigley.   

Abstract

DNA gyrase, an enzyme unique to prokaryotes, has been implicated in almost all processes that involve DNA. Although efficient inhibitors of this protein have been known for more than 20 years, none of them have enjoyed prolonged pharmaceutical success. It is only recently that the mechanisms of inhibition for some of these classes of drugs have been established unequivocally by X-ray crystallography. It is hoped that this detailed structural information will assist the design of novel, effective inhibitors of DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760340     DOI: 10.1002/bies.950180810

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  21 in total

1.  GyrI: a counter-defensive strategy against proteinaceous inhibitors of DNA gyrase.

Authors:  Monalisa Chatterji; Valakunja Nagaraja
Journal:  EMBO Rep       Date:  2002-02-15       Impact factor: 8.807

2.  The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure.

Authors:  Danielle P Cavalcanti; Stênio P Fragoso; Samuel Goldenberg; Wanderley de Souza; Maria Cristina M Motta
Journal:  Parasitol Res       Date:  2004-10-28       Impact factor: 2.289

Review 3.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

4.  Simultaneous estimation of degree of crystallinity in combination drug product of abacavir, lamivudine and neverapine using X-ray powder diffraction technique.

Authors:  Pavan Kommavarapu; Arthanareeswari Maruthapillai; Ravikiran Allada; Kamaraj Palanisamy; Praveen Chappa
Journal:  J Young Pharm       Date:  2013-11-14

5.  Competitive Growth Enhances Conditional Growth Mutant Sensitivity to Antibiotics and Exposes a Two-Component System as an Emerging Antibacterial Target in Burkholderia cenocepacia.

Authors:  April S Gislason; Matthew Choy; Ruhi A M Bloodworth; Wubin Qu; Maria S Stietz; Xuan Li; Chenggang Zhang; Silvia T Cardona
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

Authors:  Huiping Zhao; Alison C Donnelly; Bhaskar R Kusuma; Gary E L Brandt; Douglas Brown; Roger A Rajewski; George Vielhauer; Jeffrey Holzbeierlein; Mark S Cohen; Brian S J Blagg
Journal:  J Med Chem       Date:  2011-05-09       Impact factor: 7.446

7.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Biological activities of novel gyrase inhibitors of the aminocoumarin class.

Authors:  Christine Anderle; Martin Stieger; Matthew Burrell; Stefan Reinelt; Anthony Maxwell; Malcolm Page; Lutz Heide
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

10.  Mechanism of action-based classification of antibiotics using high-content bacterial image analysis.

Authors:  Kelly C Peach; Walter M Bray; Dustin Winslow; Peter F Linington; Roger G Linington
Journal:  Mol Biosyst       Date:  2013-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.